Testing new combination treatments for advanced esophageal cancer

Plain-English translation of NCT06474468 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called SHR-A2102 combined with another drug called Adebrelimab to treat advanced or metastatic esophageal cancer. Some participants will also receive chemotherapy along with these medications. The researchers want to find the safest dose of the medication and understand how well this combination works for people whose esophageal cancer has spread or cannot be surgically removed.

Current treatments for advanced esophageal cancer have limited effectiveness, and doctors need new options that work better. This trial explores whether combining these newer medications might help patients live longer and better lives.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic esophageal squamous cell cancer that cannot be surgically removed
you are between 18 and 70 years old
you have at least one measurable tumor visible on imaging scans
your overall health status is good enough to tolerate treatment (ECOG score of 0 or 1)
your doctors expect you to live at least 12 more weeks
you have adequate organ function and are willing to provide tumor tissue for testing

You likely don't qualify if…

you have untreated or uncontrolled cancer that has spread to your brain
you have severe fluid buildup in your abdomen or around your heart or lungs
you have had a history of holes in your gastrointestinal tract or serious tumor invasion into major blood vessels or airways within the past 6 months
you received chemotherapy or other cancer treatment within the past 4 weeks
you are currently taking medications that significantly interact with the study drugs, or you received live vaccines within the past 28 days

What participation looks like

Participants will receive injections of the new medication combination, either alone or combined with chemotherapy, at a hospital or clinic. You will have regular visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and check for side effects. The trial involves two treatment groups, and your doctor will discuss which option may be right for you based on your specific situation.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong